Coverage Policies

Use the index below to search for coverage information on specific medical conditions.

Note: For Arkansas State or Public School employees, services subject to pre-authorization are managed by Active Health Management, as noted in their Summary Plan Description.

For coverage information on high tech imaging (MRI, CT, PET) and nuclear medicine, administered by Evicore, click here.

Medical Providers: Payment for care or services is based on eligibility, medical necessity and available benefits at time of service and is subject to all contractual exclusions and limitations, including pre-existing conditions if applicable.

Future eligibility cannot be guaranteed and should be rechecked at time of service. Verify benefits by signing into My Account or calling Customer Service at 800.235.7111 or 501.228.7111.

If not specified in a QualChoice coverage policy (Benefit Interpretation), QualChoice follows care guidelines published by MCG Health.

QualChoice reserves the right to alter, amend, change or supplement medical policies as needed. QualChoice reviews and authorizes services and substances. CPT and HCPCS codes are listed as a convenience and any absent, new or changed codes do not alter the intent of the policy.

INDEX:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Effective Date: 10/01/2014 Title: Cyramza (Ramucir4umab)
Revision Date: 11/01/2016 Document: BI458:00
CPT Code(s): J9308
Public Statement

Effective Date:

a)    This policy will apply to all services performed on or after the above revision date which will become the new effective date.

b)    For all services referred to in this policy that were performed before the revision date, contact customer service for the rules that would apply.

1)    Cyramza (Ramucirumab) requires prior authorization.

2)    Cyramza is used to treat advanced gastric cancers, colorectal cancer, and lung cancer.

3)    Cyramza is a specialty drug covered under the medical benefit.


Medical Statement

Cyramza is considered medically necessary for members who meet the following criteria:

 

1)    Member has a diagnosis of advanced gastric cancer or gastro-esophageal junction adenocarcinoma  AND

2)    Member had disease progression or intolerance to a prior chemotherapy regimen containing a fluoropyrimidine- or platinum-agent

OR

3)    Member has diagnosis of metastatic colorectal cancer AND

4)    Member has experienced disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, in combination with irinotecan, folinic acid (leucovorin), and 5-fluourouracil. 

OR

5)    Member has a diagnosis of metastatic non-small cell lung cancer (NSCLC) AND

6)    Will be used in combination with docetaxel AND

7)    Has experience disease progression on or after platinum-based chemotherapy

 

Reauthorization (after 12 months) will be provided for members who have not experienced any of the following:

1)    Severe bleeding

2)    Grade 3 or 4 infusion-related reactions

3)    Severe hypertension that cannot be controlled with optimized antihypertensive therapy

4)    Urine protein level >3 g/24 hours or in the setting of nephrotic syndrome

5)    Arterial Thrombolic events

6)    Gastrointestinal perforation

 

Codes Used In This BI:

 

J9308 – Injection, Ramucirumab, 5mg (Cyramza)


Reference

1)    Cyramza Prescribing Information.  Eli Lilly.  April 2015.

2)    Clinical Pharmacology.  Accessed online August 2016.

3)    Fuchs CS, Tomasek J, Young CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomized, multicenter, placebo-controlled, phase 3 trial. Lancet. 2014:383:31-39.

4)    NCCN Drug Compendium .  Accessed online August 2016.


Application to Products

This policy applies to all health plans and products administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet.  Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) or Certificate of Coverage (COC) for those plans or products insured by QualChoice.  In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC or COC, the SPD, EOC, or COC, as applicable, will prevail.  State and federal mandates will be followed as they apply.


Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.
This policy has recently been updated. Please use the index above or enter policy title in search bar for the latest version.